Developing treatments to protect against rabies and related viruses
Pan-lyssavirus therapeutics and mechanisms of protection against lyssaviruses
This study is exploring a new way to help the immune system fight off rabies and similar viruses by testing a special protein that could lead to better treatments for people who have been exposed to these dangerous viruses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11026410 on NIH RePORTER |
What this research studies
This research focuses on creating new therapeutic options for rabies and other lyssaviruses, which are highly lethal without treatment. The team is investigating a novel chimeric glycoprotein designed to stimulate the immune system to produce antibodies that can neutralize these viruses. By understanding how these antibodies work, the research aims to enhance protection against rabies and its related strains, potentially leading to improved treatment protocols for exposed individuals. The study includes various experimental approaches to assess the effectiveness of these new treatments in animal models.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have been exposed to rabies or lyssaviruses and are seeking new treatment options.
Not a fit: Patients who have already received effective rabies vaccinations or treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments for rabies and related viruses, significantly reducing mortality rates.
How similar studies have performed: Previous research has shown promise in developing similar antibody-based therapies for viral infections, indicating potential for success in this area.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Schnell, Matthias Johannes — Thomas Jefferson University
- Study coordinator: Schnell, Matthias Johannes
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.